NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications
29 sept. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 29, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting
22 sept. 2016 16h01 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
19 sept. 2016 09h28 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 19, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
25 août 2016 07h25 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
25 août 2016 07h18 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
11 août 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
27 juil. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, July 27, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease
26 juil. 2016 08h07 HE
|
NeuroDerm Ltd.
- ND0701 complements the company’s product pipeline for the treatment of advanced Parkinson's disease - - ND0701's proprietary formulation is designed to improve patient convenience by allowing...
NeuroDerm Announces Additions to Management Team
06 juil. 2016 11h02 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, July 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced...
NeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13
05 juil. 2016 09h04 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...